tepotinib
merck
['nsclc', 'tepotinib', 'sclc']
this large nonrandomized clinical trial of patients with metex14-skipping nsclc supports global approvals of tepotinib, enabling clinicians to implement these therapeutic approaches. #asco23 #asco2023 #meded #medtwitter #oncology #clinicaltrials 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News